Results 191 to 200 of about 366,533 (301)

Activation of Invariant Natural Killer T Cells Enhances Ischemia-Reperfusion Injury in Steatotic Mouse Livers. [PDF]

In Vivo
Kuroda YU, Ito Y, Nishizawa N, Tanabe M, Goto T, Yamashita A, Hosono K, Satoh M, Kumamoto Y, Hiki N, Amano H.   +10 more
europepmc   +1 more source

Targeting adrenergic receptors to mitigate invariant natural killer T cells-induced acute liver injury. [PDF]

iScience, 2023
Gonzatti MB, Freire BM, Antunes MM, de Menezes GB, Talbot J, Peron JPS, Basso AS, Keller AC.   +7 more
europepmc   +1 more source

Engineered Bacteria Factory Integrating Drug Delivery and Antibody Manufacture for Activating the STING Signal Pathway Mediated Tumor Immunotherapy

Advanced Science, EarlyView.
To address the limitations of protein‐based ICIs in applications, this study constructed an engineered bacterium, HRB, capable of expressing aCD47 in hypoxic TME. Through the Schiff base reaction, responsive liposomes (LC) loaded with the STING agonist cGAMP were connected to the surface of bacteria to form HRB@LC.
Peng‐Shuo Dong, Tian Yao, Yong Li, Zi‐Hui Yan, Xiao‐Ting Xie, Jia‐Hua Zou, Kai Cheng, Jin‐Xuan Fan, Yuan‐Di Zhao, Qiu‐Ran Xu   +9 more
wiley   +1 more source

Characterizing Kupffer Cell Production of CD5 Antigen-Like and Its Function on Regulating Migration of Natural Killer T Cells. [PDF]

Am J Pathol
Hong H, Tu T, Alhousari D, He L, Aggarwal R, Debebe A, Chen CY, Ashouri K, Martynova A, Nakhoul C, Rastegarpour A, Baharlouei S, Peng D, Stile EX, Razaviyayn M, Suen SC, Cadenas E, Alachkar H, Yuan W, Machida K, Tsukamoto H, Yuan L, El-Khoueiry A, Stiles BL.   +23 more
europepmc   +1 more source

A Radioresistant‐Tumor‐Targeted Nanoparticle for X‐Ray‐Controlled Nitric Oxide Release to Potentiate Radiotherapy

Advanced Science, EarlyView.
The PBTN targets GRP78 and, upon X‐ray irradiation, generates ONOO− to induce immunogenic cell death, thereby activating CD8+ T cells and establishing a systemic antitumor immune response. ABSTRACT Nitric oxide (NO) treated radioresistant tumors by relieving hypoxia and blocking DNA repair, but its nonselective toxicity has precluded therapeutic use ...
Wanze Zhang, Xiaoyan Yin, Ting Wang, Hongfu Zhao, Zhipeng Zhao, Jinbao Wang, Cheng Tao, Xuanchu Ge, Yanze Li, Linlin Liu, Fuxin Xue   +10 more
wiley   +1 more source

α-GalCer-LNP ehanced mRNA delivery and activates natural killer T cells for superior tumor immunotherapy. [PDF]

Mater Today Bio
Zhang K, Xu Z, Xiao Z, Cao F, Wang J, Xu Y, Ma WMJ, Long S, Zha GF.   +8 more
europepmc   +1 more source

Current Developments in the Preclinical and Clinical use of Natural Killer T cells. [PDF]

BioDrugs, 2023
Kratzmeier C, Singh S, Asiedu EB, Webb TJ.   +3 more
europepmc   +1 more source

Invariant Natural Killer T-Cell [PDF]

, 2020
openaire   +1 more source

The AUTACE That Degrades KRAS and Engages CD8+ T Cells for the Treatment of KRAS/TP53 Co‐Mutant Tumors

Advanced Science, EarlyView.
AUTACE is a bifunctional nanoplatform that integrates tumor targeting, immune engagement, and on‐demand KRAS degradation. It targets KRAS/TP53 co‐mutant tumors via TP53‐specific TCRs, elicits antitumor CD8+ T‐cell responses through surface anti‐CD3 antibodies, and uses low‐intensity focused ultrasound (LIFU) to trigger controlled release of the KRAS ...
Luo Li, Bolin Li, Yanan Hao, Bo Pang, Pan Li, Chunli Li, Yu Tang   +6 more
wiley   +1 more source

Author Correction: Cancer-associated fibroblasts express CD1d and activate invariant natural killer T cells under cellular stress. [PDF]

Cell Mol Immunol
Pei S, Sjölund J, Pan Y, Pietras K, Karlsson MCI.   +4 more
europepmc   +1 more source